Skip to Main Content

Pharmaceutical Diversion – Risks and Steps to Address a Major DEA Focus

Date: 21 March 2016
Government Enforcement Alert
By: Patrick C. McCooe, Michael D. Ricciuti

Introduction
The opioid crisis, an ever-increasing focus of the Obama administration and 2016 Presidential Primary field, has highlighted the efforts of the Drug Enforcement Administration (DEA) and the Department of Justice (DOJ) to address diversion of pharmaceuticals classified as controlled substances, which has long been a major DEA priority.  Criminal and civil cases brought or settled by DEA and DOJ show the substantial risks involved for those in the chain of distribution of pharmaceuticals subject to the Controlled Substances Act.  The following is a practical summary of these issues.

Click here to read the full alert.

This publication/newsletter is for informational purposes and does not contain or convey legal advice. The information herein should not be used or relied upon in regard to any particular facts or circumstances without first consulting a lawyer. Any views expressed herein are those of the author(s) and not necessarily those of the law firm's clients.

Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel